Revenue

medicine

Precision Medicine Market Size, Share, Trends | Opportunities, Demands and Growth Revenue by 2026 | Brandessence Market Research Report

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (Heraldkeepers) —
The Precision Medicine Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Precision Medicine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment; technological innovation and advancement , as well as growth of personal healthcare devices are major key factor which drives the Global Precision Medicine Market.

Get Sample Copy of This Premium Report https://brandessenceresearch.com/requestSample/PostId/55

**The sample pages of this report is immediately accessible on-demand.**

Top Precision Medicine companies:

key strategies followed by the top players operating in the precision medicine market are,

  • Abbott Laboratories
  • GE Healthcare
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Pfizer
  • Laboratories Corporation of America Holdings
  • Danaher Corporation
  • Biocrates Life Sciences AG
  • Nanostring Technologies
  • Intomics
  • Ferrer Incode
  • Eagle Genomics Ltd

Scope of Market Reports –

Precision medicine is often called as Personalized Medicine. It is used to describe how genetic information about a person’s disease is being used to diagnose or treat their disease. Precision Medicine refers to the modification of medical treatment to the individual characteristics of each patient. It does not exactly mean the manufacturing of drugs or medical devices that are unique to a patient, but the ability to categorize individuals into sub-populations that diverge in their susceptibility to a particular disease. Preventive or therapeutic interventions can then be focused on those who will benefit, sparing cost and side effects for those who will not. The main aim of government regulations is to make Precision Medicines more accepted and it is focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases.

The key objective of Cancergenomics is to improve personalized medicine through the DNA sequencing and analysis of patient tumors cells to find out new genetic mutation associated with specific cancers.

Genetic information has helped to increase the development and use of the newest cancer treatments like Chemotherapy, Radiation Therapy, Targeted Therapy and Precision Medicines. For example, the drug Imatinib was modified to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenousleukemia. Another example is the breast cancer drug Trastuzumab which works only for women whose tumors have a particular genetic profile calledHuman Epidermal Growth Factor Receptor 2(HER-2 positive). It is also found that lung cancer patients whose tumors are positive forEstimated Glomerular Filtration Rate (EGFR)mutations will respond to the drugs Gefitinib and Erlotinib which target this mutation. Conversely, colon cancer patients whose tumors have a mutation in a gene called KRAS (K-RAS) derive less benefit from the drugs Cetuximab and Panitumumab. The genomic information made by The Cancer Genome Atlas (TCGA) will boostthe research to develop similar treatment strategies for

Read More
medicine

Bioelectric Medicine Market Size, Share Report 2020 Shipments, Price, Revenue and Gross profit till 2025 With Impact of COVID-19

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Bioelectric Medicine Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Bioelectric Medicine Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Bioelectric Medicine market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Bioelectric Medicine industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16705148

In Regional Analysis, the Bioelectric Medicine market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Bioelectric Medicine market throughout the forecast length. The Bioelectric Medicine market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Bioelectric Medicine Market: – https://www.industryresearch.co/enquiry/request-covid19/16705148

Bioelectric Medicine market report provides in-depth data about company Profiles, Bioelectric Medicine launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Bioelectric Medicine market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Bioelectric Medicine market covered in report:

● Nevro ● Second Sight Medical Products ● Sonova Holding ● St. Jude Medical ● Medtronic ● Cochlear ● Electrocore ● Boston Scientific Corporation ● Livanova ● Biotronik

On the basis of types, the Bioelectric Medicine market from 2015 to 2025 is primarily split into:

● Implantable Cardioverter Defibrillators ● Cardiac Pacemakers ● Spinal Cord Stimulators ● Cochlear Implants ● Deep Brain Stimulators ● Transcutaneous Electrical Nerve Stimulators ● Vagus Nerve Stimulators ● Sacral Nerve Stimulators ● Retinal Implants ● Other Electrical Stimulators

On the basis of applications, the Bioelectric Medicine market from 2015 to 2025 covers:

● Hospitals ● Research Institutes ● Individual Users

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16705148

Bioelectric Medicine Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Bioelectric Medicine Market report describes present situation, historical background and future forecast. It Comprehensive data showing Bioelectric Medicine sale, consumption, trade statistics, and prices in the recent years are provided. The Bioelectric Medicine report indicates a wealth of information on Bioelectric Medicine vendors. Bioelectric Medicine Market forecast for next five years, including Market volumes

Read More
medicine

Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read More
medicine

Precision Medicine Market: Future Scope, Revenue Growth, Global Market Size, Market Status, Top key players, end of 2027

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Wed, 11 Nov 2020 06:07:57 / Comserve Inc. / — The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region.

Recent report published by research nester titled “Precision Medicine Market: Global Demand Analysis & Opportunity Outlook 2027″delivers the detailed overview of the global precision medicine market in terms of market segmentation by product, by technology, by sequencing technology, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region. On the basis of product, it is sub-segmented into instruments, consumables and services. Based on technology, it is sub-segmented into transcriptomics, genomics and epigenomics. On the basis of sequencing technology, it is sub-segmented into ion semiconductor sequencing, pyrosequencing, single molecule real time Sequencing, chain termination sequencing, sequencing by synthesis, sequencing by ligation and nanopore sequencing. CLICK TO DOWNLOAD SAMPLE

Based on application, it is sub-segmented into immunology, CNS, oncology, respiratory medicine, infections and others. On the basis of end user, it is sub-segmented into pharma & biotech companies, diagnostic tool companies, big data companies and clinical laboratories. The market across the globe is exclusively focusing to provide specific tailored treatments to patients are also concentrating on proving the best possible treatment for cancer patients. These factors are anticipated to boost the growth of the global precision medicine market in upcoming years.

The global precision medicine market is anticipated to expand at a CAGR around 10.6% during 2019-2027. Increment in the growth of personal healthcare devices along with rise in investment in the research and development is expected to augment the market shares. Further, the rapid development in the field of bioinformatics combined with high adoption rate of gene therapy are some of the significant factors that are estimated to positively affect the growth of the market.

By region, the global precision medicine market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. Among these region, North America is expected to dominate the global market of precision medicine on account of increasing cases related to rare genetic disorders and various initiatives taken by the regulatory bodies in support of the market. Further, the rising investment in the research and development in the field of precision medicine coupled with rising healthcare infrastructure are some of the factors that are augmenting the growth of market in this region. In the Europe region, Germany is expected to have the largest market share on the back of rising pediatric and adult population susceptible to metabolic diseases. Additionally, rising investment in the healthcare sector by various private and government organizations coupled with various technological advancements in this field is anticipated to

Read More
medicine

Precision Medicine Market: Emerging Trends, Growth Insight, Comprehensive Insights, Rising Demand, Industry Trends & Revenue Models, 2027

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Wed, 11 Nov 2020 05:23:43 / Comserve Inc. / — The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region.

Recent report published by research nester titled “Precision Medicine Market: Global Demand Analysis & Opportunity Outlook 2027″delivers the detailed overview of the global precision medicine market in terms of market segmentation by product, by technology, by sequencing technology, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region. On the basis of product, it is sub-segmented into instruments, consumables and services. Based on technology, it is sub-segmented into transcriptomics, genomics and epigenomics. On the basis of sequencing technology, it is sub-segmented into ion semiconductor sequencing, pyrosequencing, single molecule real time Sequencing, chain termination sequencing, sequencing by synthesis, sequencing by ligation and nanopore sequencing. CLICK TO DOWNLOAD SAMPLE

Based on application, it is sub-segmented into immunology, CNS, oncology, respiratory medicine, infections and others. On the basis of end user, it is sub-segmented into pharma & biotech companies, diagnostic tool companies, big data companies and clinical laboratories. The market across the globe is exclusively focusing to provide specific tailored treatments to patients are also concentrating on proving the best possible treatment for cancer patients. These factors are anticipated to boost the growth of the global precision medicine market in upcoming years.

The global precision medicine market is anticipated to expand at a CAGR around 10.6% during 2019-2027. Increment in the growth of personal healthcare devices along with rise in investment in the research and development is expected to augment the market shares. Further, the rapid development in the field of bioinformatics combined with high adoption rate of gene therapy are some of the significant factors that are estimated to positively affect the growth of the market.

By region, the global precision medicine market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. Among these region, North America is expected to dominate the global market of precision medicine on account of increasing cases related to rare genetic disorders and various initiatives taken by the regulatory bodies in support of the market. Further, the rising investment in the research and development in the field of precision medicine coupled with rising healthcare infrastructure are some of the factors that are augmenting the growth of market in this region. In the Europe region, Germany is expected to have the largest market share on the back of rising pediatric and adult population susceptible to metabolic diseases. Additionally, rising investment in the healthcare sector by various private and government organizations coupled with various technological advancements in this field is anticipated to

Read More
medicine

Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates

Editas Medicine (EDIT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 118.18%. A quarter ago, it was expected that this genome editing company would post a loss of $0.80 per share when it actually produced a loss of $0.43, delivering a surprise of 46.25%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Editas, which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $62.84 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 759.42%. This compares to year-ago revenues of $3.85 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Editas shares have added about 2.8% since the beginning of the year versus the S&P 500’s gain of 6.6%.

What’s Next for Editas?

While Editas has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Editas was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.89 on $6.57 million in revenues for the coming quarter and -$2.67 on $29.49 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform

Read More
health

Sinus Dilation Devices Market revenue to cross USD 3.3 Bn by 2026: Global Market Insights, Inc.

China sinus dilation devices market is estimated to show significant growth of 11.6% till 2026 on account of a large patient base prone to chronic sinusitis disorder along with increase in healthcare expenditure across the country

Selbyville, Delaware, Nov. 03, 2020 (GLOBE NEWSWIRE) —

According to latest report “Sinus Dilation Devices Market Product (Balloon Sinus Dilation Devices, Sinus Implants, Handheld Instruments, Sinuscopes, Rhinoscopes), Procedure (Standalone Sinus Dilation Procedures, Hybrid Sinus Dilation Procedures), End-use (Hospital, Physicians Office, Ambulatory Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026”, by Global Market Insights, Inc., the market valuation of sinus dilation devices will cross $3.3 billion by 2026.

Increasing number of patients suffering from sinusitis will propel the industry growth in the coming years. With rising prevalence of sinusitis, high inflow of patients in ENT clinics and hospitals are leading to increased adoption of sinus dilation devices among physicians. According to a report by the National Institutes of Health, each year approximately 37 million people in the U.S. are affected by chronic rhinosinusitis. Moreover, growing prevalence of chronic sinusitis has compelled the manufacturers to expand their business by developing advanced sinus dilation devices.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2749

Growing technological advancements, reimbursement policies for sinus dilation procedures and rising demand for cost-effective treatments are further driving the sinus dilation devices market growth. Increasing geriatric population coupled with rising prevalence of chronic diseases will further augment the demand for sinus dilation devices.

Balloon sinus dilation devices segment valued over USD 610 million in 2019 led by the increased preference for balloon sinus dilation procedures owing to its high safety and efficacy. The medical and insurance companies provide reimbursement for procedures requiring the use of balloon sinus dilation devices. In addition, these devices are preferred due to additional benefits such as less risk of post-operative infection, reduced dependence on pain medications, and limited risk of tissue damage or scarring.

The standalone sinus dilation procedure segment valuation was more than USD 1,372 million in 2019 driven by rising prevalence of osteitis in sinuses, that has led to a significant rise in the number of standalone balloon sinus ostial dilation (BSOD) procedures performed each year. Standard sinus dilation procedures are proven to be safe, effective and a better alternative to functional endoscopic sinus surgery (FESS). Standalone sinus procedures have very low surgical revision rates with 1-year follow up and hence, patients increasingly prefer to undergo standalone sinus dilation procedures.

Hospital end-use segment in the sinus dilation devices market exceeded USD 902 million in 2019impelled by the growing number of outpatient sinus dilation procedures along with rising healthcare professionals in hospitals with the ability to perform complex sinus procedures. The ongoing pandemic has led to an exponential increase in number of patients suffering from sinusitis. This in-turn has fueled the demand for sinus dilation procedures in the hospital settings.

China sinus dilation devices market is estimated to show significant growth at 11.6% till 2026 on account of a

Read More
health

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

  • Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of type 2 diabetes in July 2020 and a target launch is expected in fiscal year 20211; a milestone payment of EUR 4 million was received in Q3 2020 from Sumitomo Dainippon Pharma

  • Imeglimin Phase 3 TIMES results were presented at the 56th European Association for the Study of Diabetes (EASD) meeting; Phase 2b, Phase 3 TIMES results, and additional safety data were presented at the 63rd Annual Meeting of Japanese Diabetes Society (JDS)

  • PXL770 Phase 2a trial for the treatment of NASH met its primary efficacy endpoint and trial objectives, and it was observed to be safe and well tolerated

  • PXL770 profile supports development in NASH and also further evaluation for combination use, as well as utility of adenosine monophosphate-activated protein kinase (AMPK) activation in other chronic and rare metabolic diseases

  • PXL065 Phase 2 trial was initiated in biopsy-proven NASH patients in September 2020; streamlined development with a single Phase 2 trial given knowledge of pioglitazone, including data in NASH, and 505(b)(2) regulatory pathway, which offers the opportunity for an efficient and lower risk development program

  • As of September 30, 2020, cash and cash equivalents were EUR 41.5 million (USD 48.6 million)

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2020.

“During the third quarter, we continued to make significant progress and accomplished a number of important clinical and corporate objectives, including reporting positive results from a Phase 2a proof-of-concept trial for PXL770, demonstrating its potential in NASH. These results are the first human clinical assessment of a direct AMPK activator and support longer-term evaluation of important histological endpoints, such as inflammation and fibrosis, and exploring subpopulations for further differentiation. The data also demonstrate that AMPK activation may lead to broader utility for the treatment of other chronic and rare metabolic diseases. In addition, we initiated a streamlined Phase 2 trial for PXL065 in NASH and strengthened our cash position with non-dilutive funding from a milestone payment of EUR 4 million for the Imeglimin New Drug Application (NDA) submission in Japan and the recent PGE loan of EUR 6 million from the French government,” said Thomas Kuhn, CEO of Poxel.

“For the remainder of this year, we expect several upcoming milestones and events including finalization of the PXL770 Phase 2b clinical trial design, presentations for PXL770 and PXL065 at several scientific meetings as well as publishing results in peer-reviewed scientific journals and additional preclinical data related to our AMPK and deuterated-TZD platforms. Furthermore, our partner, Metavant, is in discussions with the U.S. Food and Drug Administration (FDA) regarding the Imeglimin Phase 3 program in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4,” added Thomas Kuhn,

Read More